Primary outcome analysis
Nasal Obstruction
Patient reported symptoms improved in both groups. In those participants randomised to receive septoplasty in the ITT population (n=152), mean SNOT-22 scores were 44.5 (95% confidence interval 41.1 to 47.8) at baseline and 19.9 (17.0 to 22.7) at six months. The corresponding scores for those participants randomised to receive medical management in the ITT population (n=155) were 44.1 (40.8 to 47.4) and 39.5 (36.1 to 42.9). Baseline SNOT-22 scores were approximately symmetrically distributed about the mean and were not transformed for the analysis (see supplementary material figures S2 and S3). In the primary ITT analysis, participants randomised to the septoplasty group reported on average 20.0 units greater improvement in symptoms compared with those randomised to the medical management group, as measured by SNOT-22 (95% confidence interval improvement 16.4 to 23.6, P<0.001; Patient reported SNOT-22 score at six months (primary outcome) adjusted for baseline SNOT-22 score and stratification variables sex and NOSE categories in 307 participants in intention-to-treat populationNOSE=Nasal Obstruction and Symptom Evaluation scale; SNOT-22=Sino-Nasal Outcome Test-22.Adjusted RThe planned population defining analyses all showed similar results and supported the primary ITT analysis (Forest plot of primary analysis and sensitivity analysis for intention-to-treat population. CI=confidence interval